Recent progress in the development of plant derived vaccines.
Recombinant subunit vaccines have been with us for the last 30 years and they provide us with the unique opportunity to choose from the many available production systems that can be used for recombinant protein expression. Plants have become an attractive production platform for recombinant biopharmaceuticals and vaccines have been at the forefront of this new and expanding industry sector. The particular advantages of plant-based vaccines in terms of cost, safety and scalability are discussed in the light of recent successful clinical trials and the likely impact of plant systems on the vaccine industry is evaluated.
Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way, Suite 200, Newark, DE 1971, USA. vyusibov@fraunhofer-cmb.org
Vidadi
V
Yusibov
Shailaja
S
Rabindran
D006801:Humans; D010944:Plants / Q000235:genetics / Q000378:metabolism*; D014481:United States; D022223:Vaccines, Subunit / Q000009:adverse effects / Q000096:biosynthesis* / Q000191:economics / Q000235:genetics; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000096:biosynthesis* / Q000191:economics / Q000235:genetics
D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic